ࡱ> LNK (.bjbjtWtW 5@=g=g lllll,\63555555$&!<YQlYllgggll3g3ggg "W,^g0g"("g"lggYY?("X 2: @Supplementary Table 2. Characteristics of the randomized controlled trials included in the non-Asian subgroup. First author Trial duration Diabetes duration Age Male (%) Number of Dosage HbA1c at baseline (%) BMI at baseline kg/3 FPG, mmol/L (year) (weeks) (years) (years) patients SGLT2-i MET SGLT2-i MET SGLT2-i MET SGLT2-i MET SGLT2-i MET SGLT2-i MET SGLT2-i MET SGLT2-i MET plus MET monotherapy plus MET monotherapy plus MET monotherapy plus MET monotherapy (mg/day) (mg/day) plus MET monotherapy plus MET monotherapy plus MET monotherapyJulio Rosenstock 2016 26 2.93.3 3.34.5 54.2 9.6 55.2 9.8 45.6 48.9 235 230 CANA 100 e"1500 8.81.1 8.81.2 31.95.3 33.06.0 10.62.8 10.62.7S. Ross 2015 16 -------- ------- -------- -------- ----- ----- 214 107 EMPA 25 e"1500 7.730.05 7.690.07 -------- -------- 8.70.1 8.90.2N. B. Amin 2015 12 6.0 6.4 54.28.8 548.1 67.3 55.6 55 54 ERTU 25 <3000 8.300.16 8.080.14 29.80.67 30.60.61 9.520.43 9.180.31Julio Rosenstock 2018 26 8.15.5 8.06.3 56.99.4 56.58.7 45.4 46.9 205 209 ERTU 15  mno  n r    & ' Z [ & ' [ \ ] r s {  dz&h`B*CJKHOJQJaJo(ph# #h`B*CJKHOJQJaJph&h`B*CJKHOJQJaJo(ph7h3|h`5B*CJKHOJPJQJ\_HaJph# 7h3|h3|5B*CJKHOJPJQJ\_HaJph# 3o \  $&#$/IfWD` b$l )$$&#$/IfVDdWD^`a$b$l '$$&#$/IfWDj^`a$b$l  . dWD`. \ ] d!$dh$&#$/1$Ifa$b$l xkd$$IfGhH  6 0hH44 lae4p  "*.0>JZdt~$&@B\`rx *Xܶܶܶܶ#h`B*CJKHOJQJaJph# &h`B*CJKHOJQJaJo(ph# #h`B*CJKHOJQJaJph&h`B*CJKHOJQJaJo(phh`CJKHOJQJaJo(@i$$&#$/1$Ifa$b$l vkd$$IfGhH  6 0hH44 lae4p 04`dz|*VXZ26LNbdnz|$$$$$P%V%%%%%%%%%%t&v&x&&&&& '$'P'T'h'j''''''''شU#h`B*CJKHOJQJaJph# #h`B*CJKHOJQJaJph&h`B*CJKHOJQJaJo(ph# &h`B*CJKHOJQJaJo(phFXf!$d$&#$/1$Ifa$b$l vkdf$$IfGhH  6 0hH44 lae4p XZ$f!$d$&#$/1$Ifa$b$l vkd$$IfGhH  6 0hH44 lae4p e"1500 8.10.9 8.20.9 31.14.5 30.74.7 9.32.5 9.42.3Marina V. 2018 12 6.15.9 5.85.3 58.99.3 58.09.5 43.6 40.0 110 55 IPRA 50 e"1500 8.390.93 8.460.96 32.84.76 31.954.2 9.492.25 9.762.4J.P. H. Wilding 2012 12 6.05.3 5.73.2 58.67.6 57.38.6 47.1 54.5 68 66 IPRA 50 e"1500 7.760.66 7.680.60 31.14.9 32.04.8 8.52.0 8.61.5R.R.Henry 2012 24 2.23.3 1.94.0 51.010.1 51.010.1 50.2 46.6 211 208 DAPA 10 e"1500 9.11.3 9.11.3 --------- --------- 10.523.22 10.573.0Schumm-Draeger 2015 16 5.124.2 5.534.23 55.39.3 58.59.4 46.5 46.5 99 101 DAPA 10 e"1500 7.780.76 7.940.85 33.094.94 31.744.7 8.621.77 8.761.99 CANA, canagliflozin; DAPA, dapagliflozin; EMPA, empagliflozin; ERTU, ertugliflozin; IPRA, ipragliflozin; MET, metformin; BMI, body mass index; FPG, fasting plasma glucose;Data are mean SD or mean; SD, standard deviation. $$v&kd$&#$/Ifb$l vkd$$IfGhH  6 0hH44 lae4p v&x&B(kd$&#$/Ifb$l vkdd$$IfGhH  6 0hH44 lae4p '@(B(D(d(f(t(((((((((((((((())))$)4)6)J)L)V)Z)`)b)d)v)x)))))))))***@*D*V*Z******Ʒأ#h`B*CJKHOJQJaJph&h`B*CJKHOJQJaJo(phh`CJKHOJQJaJo(#h`B*CJKHOJQJaJph&h`B*CJKHOJQJaJo(ph# &h`B*CJKHOJQJaJo(ph9B(D(*f!$dh$&#$/1$Ifa$b$l vkd$$IfGhH  6 0hH44 lae4p **+f!$dh$&#$/1$Ifa$b$l vkd$$IfGhH  6 0hH44 lae4p *****++++(+4+6+~++++++++++,,,,, , ,,,,,,,,,, ,D,,- -6-8-b-d---..&.(.h`h`CJOJQJaJh`CJ_HaJ#h`B*CJKH^J_HaJphh`CJOJQJ_HaJ h`o(&h`B*CJKHOJQJaJo(ph# #h`B*CJKHOJQJaJph&h`B*CJKHOJQJaJo(ph4++++++,,,,, , ,,,,vkdb$$IfGhH  6 0hH44 lae4p ,,,,,,, ,8-.(. pdWD`pd 3182P0w A! " #$%S $$If!vh#vhH:V   6 0hH5hH/ /  ae4p $$If!vh#vhH:V  6 0hH5hH/ ae4p $$If!vh#vhH:V  6 0hH5hH/ ae4p $$If!vh#vhH:V  6 0hH5hH/ ae4p $$If!vh#vhH:V  6 0hH5hH/ ae4p $$If!vh#vhH:V  6 0hH5hH/ ae4p $$If!vh#vhH:V  6 0hH5hH/ ae4p $$If!vh#vhH:V  6 0hH5hH/ ae4p $$If!vh#vhH:V  6 0hH5hH/  / ae4p x66666668 0@P`p6888 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@66666PJ_HmH @nH @sH @tH @Z`Z Normal $1$a$(CJKHOJQJ_HaJmH nHsH tHDA D Default Paragraph Fonti@  Table Normal[:V 44l44l02 d1$$$ $[$\$^]CJOJQJo(^JaJtH (k ( 0No List PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭Vj\{cp/IDg6wZ0s=Dĵw %;r,qlEآyDQ"Q,=c8B,!gxMD&铁M./SAe^QשF½|SˌDإbj|E7C<bʼNpr8fnߧFrI.{1fVԅ$21(t}kJV1/ ÚQL×07#]fVIhcMZ6/Hߏ bW`Gv Ts'BCt!LQ#JxݴyJ] C:= ċ(tRQ;^e1/-/A_Y)^6(p[_&N}njzb\->;nVb*.7p]M|MMM# ud9c47=iV7̪~㦓ødfÕ 5j z'^9J{rJЃ3Ax| FU9…i3Q/B)LʾRPx)04N O'> agYeHj*kblC=hPW!alfpX OAXl:XVZbr Zy4Sw3?WӊhPxzSq]y '@ '*(. \ X$v&B(*+,(. 8@0(  B S  ?:;>?#$01=>JK)*67}~ !MNYZfgst34?@LMYZ&'34@A    & ' j k w x     S T a b o p } ~ ~ W_} ~ 3333333mn mn (`3|A "^5T!Uc m(s[6Mqm"2,!5+.#B;$ $);)D5W*G+\,f\1UD47]_ 8YcE FF{>HvECK OEq#Xb;Y@1Z^^7?c'wga+o%Mr@ uh!y @ ))))L p@p p@ppp$UnknownG.[x Times New Roman5Symbol3. .[x ArialuMinion-RegularMalgun Gothic Semilight;(SimSun[SOG..{$ CalibriCalibriC.,.{$ Calibri LightA$BCambria Math AQhӂgC  Z&!),.:;?]}    & 6"0000 0 0 00000 =@\]^([{  0 0 00000;[ 2 KP  $P3|2!xx@9 51117Aura Oh+'0X    ,8@HP51117 Normal.dotmAura2Microsoft Office Word@@9~@HcW,  ՜.+,D՜.+,, hp|     Titled ?GKSOProductBuildVer2052-11.1.0.10314  "#$%&'(*+,-./0123456789:<=>?@ABDEFGHIJMRoot Entry FW,OData !1Table)"WordDocument5@SummaryInformation(;DocumentSummaryInformation8CCompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q